Warning letter
Customceutical Compounding: warning letter of Aug 25, 2020
FDA warning letter 610092 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 610092 |
|---|---|
| Company | Customceutical Compounding |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Aug 25, 2020 |
| Posted date | Dec 22, 2020 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| Inspection city | Phoenix |
| Inspection ZIP | 85028-4258 |
| Inspection start date | Feb 27, 2019 |
| Letter on fda.gov | fda.gov |
At a glance
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: